Skip to main content
Medical information Clinical review pending

Genetic Testing

CD46 Gene Hemolytic Uremic Syndrome Atypical Type 2 Susceptibility to Genetic Test

This genetic test analyzes the CD46 gene to identify susceptibility to atypical Hemolytic Uremic Syndrome (aHUS) type 2, a rare disorder affecting the kidneys. Utilizes Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for a blood draw. Discuss any medications or supplements you are taking with your doctor.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CD46 Gene Hemolytic Uremic Syndrome Atypical Type 2 Susceptibility to Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of aHUS or related kidney disorders.
  • ✓Patients experiencing symptoms like unexplained anemia, kidney dysfunction, or neurological issues.
  • ✓Individuals undergoing genetic counseling for hereditary conditions.
  • ✓Patients seeking to understand their genetic risk for aHUS.
02

In plain language

What this test helps you understand

Identifies genetic mutations in the CD46 gene associated with susceptibility to atypical Hemolytic Uremic Syndrome (aHUS) type 2. Helps in assessing risk and guiding management for individuals with a family history or symptoms suggestive of aHUS.
The CD46 Gene Hemolytic Uremic Syndrome Atypical Type 2 Susceptibility to NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to atypical hemolytic uremic syndrome (aHUS). aHUS is a rare condition that can cause severe kidney damage and other serious health problems. Understanding your genetic susceptibility to this disorder is important for managing your health proactively.

This test specifically looks for changes (mutations) in the CD46 gene. This gene is important for regulating the immune system and protecting cells. By examining the patient's genetic information, healthcare providers can assess the risk of developing aHUS.

Results from the CD46 Gene test will show if any mutations were found. A positive result might indicate an increased risk for aHUS, while a negative result may offer reassurance. It is crucial to discuss your results with a healthcare professional to understand their implications and discuss any necessary follow-up steps, such as monitoring or treatment options.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for a blood draw. Discuss any medications or supplements you are taking with your doctor.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the CD46 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific mutations in the CD46 gene. It does not detect mutations in other genes associated with aHUS or rule out other causes of kidney disease. A negative result does not completely eliminate the risk of developing aHUS. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

aHUS is a rare and serious condition that affects the blood and kidneys, often leading to kidney failure. It can be caused by genetic mutations.
Mutations in the CD46 gene are one known cause of aHUS. Testing helps identify if an individual carries these specific genetic changes.
Individuals with a family history of aHUS, those with symptoms suggestive of the condition, or those undergoing genetic counseling for related disorders may benefit from this test.
A positive result indicates the presence of mutations in the CD46 gene associated with aHUS susceptibility. It's important to discuss this with your doctor to understand the implications.
Yes, genetic counseling before and after testing is highly recommended to help understand the test, interpret results, and discuss potential implications for you and your family.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp